The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT02943252
Phase
PHASE2
Status
Unknown

Conditions

  • Head and Neck Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib 500 mg in tablet once daily
  • S1 — DRUG
    S-1 40-60mg bid, days 1-14 , every 3 weeks

Study Details

This is a Single-center, Open-label, Single-arm, Phase Ⅱ exploratory clinical trial evaluating the efficacy and safety of Apatinib plus S1 for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous head and neck cancer.

Key Dates

Start date
Oct 31, 2016
Status verified
Oct 2016
Primary completion
Oct 31, 2019
Completion
Oct 31, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus S1
    Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).

Primary Outcome Measure

Response Rate [ Time Frame: up to 3 years ]

Central Contacts

Related Studies